Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Colorcon
McKesson
Harvard Business School
Johnson and Johnson

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Almatica Company Profile


Email this page to a colleague

« Back to Dashboard

Summary for Almatica
International Patents:64
US Patents:8
Tradenames:13
Ingredients:12
NDAs:12

Drugs and US Patents for Almatica

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Almatica GRALISE gabapentin TABLET;ORAL 022544-002 Jan 28, 2011 BX RX Yes Yes 8,192,756 ⤷  Try it Free Y ⤷  Try it Free
Almatica ZESTRIL lisinopril TABLET;ORAL 019777-005 Apr 29, 1993 AB RX Yes No ⤷  Try it Free ⤷  Try it Free
Almatica GRALISE gabapentin TABLET;ORAL 022544-002 Jan 28, 2011 BX RX Yes Yes 6,723,340 ⤷  Try it Free Y ⤷  Try it Free
Almatica NAPRELAN naproxen sodium TABLET, EXTENDED RELEASE;ORAL 020353-003 Jan 5, 1996 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free
Almatica MACROBID nitrofurantoin; nitrofurantoin, macrocrystalline CAPSULE;ORAL 020064-001 Dec 24, 1991 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free
Almatica LOREEV XR lorazepam CAPSULE, EXTENDED RELEASE;ORAL 214826-002 Aug 27, 2021 RX Yes No 8,999,393 ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Almatica

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Almatica ZESTORETIC hydrochlorothiazide; lisinopril TABLET;ORAL 019888-003 Nov 18, 1993 4,472,380 ⤷  Try it Free
Almatica ZESTRIL lisinopril TABLET;ORAL 019777-005 Apr 29, 1993 4,374,829*PED ⤷  Try it Free
Almatica ZESTORETIC hydrochlorothiazide; lisinopril TABLET;ORAL 019888-002 Jul 20, 1989 4,374,829*PED ⤷  Try it Free
Almatica NAPRELAN naproxen sodium TABLET, EXTENDED RELEASE;ORAL 020353-003 Jan 5, 1996 5,637,320 ⤷  Try it Free
Almatica ZESTRIL lisinopril TABLET;ORAL 019777-002 May 19, 1988 4,374,829*PED ⤷  Try it Free
Almatica MACROBID nitrofurantoin; nitrofurantoin, macrocrystalline CAPSULE;ORAL 020064-001 Dec 24, 1991 4,772,473 ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ALMATICA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 450 mg ➤ Subscribe 2013-02-28
➤ Subscribe Tablets 300 mg and 600 mg ➤ Subscribe 2011-10-31

Supplementary Protection Certificates for Almatica Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2316456 300918 Netherlands ⤷  Try it Free PRODUCT NAME: NALTREXON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER NALTREXONHYDROCHLORIDE, EN BUPROPION OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER BUPROPIONHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/988 20150330
2316456 C 2017 047 Romania ⤷  Try it Free PRODUCT NAME: COMBINATIE DE NALTREXONA SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTEIA, IN PARTICULAR CLORHIDRAT DE NALTREXONA SI BUPROPION SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIA, IN PARTICULAR CLORHIDRAT DE BUPROPION; NATIONAL AUTHORISATION NUMBER: EU/1/14/988; DATE OF NATIONAL AUTHORISATION: 20150326; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/988; DATE OF FIRST AUTHORISATION IN EEA: 20150326
2316456 LUC00054 Luxembourg ⤷  Try it Free PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/14/988 20150330
0454511 99C0009 Belgium ⤷  Try it Free PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
0502314 SPC/GB02/037 United Kingdom ⤷  Try it Free PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
0984957 PA2011005 Lithuania ⤷  Try it Free PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Express Scripts
Baxter
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.